Aligos Therapeutics. has been granted a patent for compounds that inhibit the PD-1/PD-L1 interaction, potentially aiding in the treatment of PD-L1 related diseases such as liver diseases, cancer, and hepatitis B. The patent includes pharmaceutical compositions featuring these compounds. GlobalData’s report on Aligos Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Aligos Therapeutics, Peptide pharmacophores was a key innovation area identified from patents. Aligos Therapeutics's grant share as of June 2024 was 9%. Grant share is based on the ratio of number of grants to total number of patents.
Inhibitors of pd-1/pd-l1 interaction for disease treatment
The granted patent US12018015B2 outlines a series of claims related to a novel compound, designated as Formula (I), which includes various structural modifications and derivatives. The claims detail specific configurations of the compound, including the presence of alkyl groups, nitrogen-containing substituents, and various functional groups such as hydroxyl and halogens. The patent also specifies the potential for the compound to exist as a pharmaceutically acceptable salt, enhancing its applicability in therapeutic contexts. Notably, the claims encompass a range of structural variations, allowing for the exploration of different chemical entities that may exhibit desired biological activities.
In addition to the structural claims, the patent describes pharmaceutical compositions that incorporate the compound, emphasizing its utility in treating specific medical conditions. The claims include methods for treating hepatitis B and hepatocellular carcinoma (HCC) by administering an effective amount of the compound or its salts to patients in need. This highlights the therapeutic potential of the compound in addressing significant health issues, particularly viral infections and liver cancer. Overall, the patent provides a comprehensive framework for the development and application of these compounds in medical treatments.
To know more about GlobalData’s detailed insights on Aligos Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
